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diverse opinions. 50% of the responses range 
over about half of the 11-point scale.
To explore the respondents’ thinking we 
asked, “In a few words, can you tell us why 
you agree or disagree with the decision.” 
Almost three out of four people added 
comments, suggesting that the topic is of 
importance. A systematic content analysis 
identified 21 broad themes (Supplementary 
Note, section 3).
For adult therapy, 75% of the comments 
were positive evaluations of gene editing 
technology. In order of frequency, these 
comments related to the following: it led to 
“improvements to quality of life”; it would 
enable “curing dementia”; and the “benefits 
outweighing the risks”. For prenatal therapy 
the proportion of support for gene editing 
declines to 60%. Positive comments for this 
type of therapy were the same as for ‘adult 
therapy’, but included additional comments, 
such as “it is natural for parents to want the 
best for their children.” Gene editing for adult 
enhancement achieves only 26% positive 
comments. On the negative side, people 
mention there is “no need; being normal or 
average is OK,” and that there might be “risks 
and unknown consequences.” Only 11% of 
comments on prenatal enhancement are 
positive. In order of frequency, the negative 
remarks say gene editing is “unnatural and 
messing with nature”; that “there is no need” 
for this type of intervention; there are “risks 
of unknown consequences”; and it is just 
“wrong.”
Might previous debates around modern 
biotech carry over into people’s thinking 
about gene editing? For example, do 
Public views on gene editing and its uses
To the Editor: Rapid advances in genome 
editing and its potential application in 
medicine and enhancement have been 
hotly debated by scientists and ethicists. 
Although it has been proposed that 
germline gene editing be discouraged for 
the time being1, the use of gene editing in 
somatic human cells in the clinical context 
remains controversial, particularly for 
interventions aimed at enhancement2. 
In a report on human genome editing, 
the US National Academies of  Sciences, 
Engineering, and Medicine (NAS; 
Washington, DC) notes that “important 
questions raised with respect to genome 
editing include how to incorporate societal 
values into salient clinical and policy 
considerations”3. We report here our 
research that opens a window onto what the 
public thinks about these issues.
We conducted online quota sample 
surveys of more than 1,000 respondents 
in Austria, Denmark, Germany, Hungary, 
Iceland, Italy, the Netherlands, Portugal, 
Spain, UK (EEA-10 countries) and the 
United States (n = 11,716; Supplementary 
Note, section 1) to elicit judgments about 
gene editing using the contrastive vignette 
method4,5. In our study, four vignettes in 
an experimental design combined two 
contexts and two recipient categories 
(Supplementary Note, section 2). The 
contexts were therapy (curing a disease) 
and enhancement (improving memory 
and learning capacity). The recipient 
categories were adult and prenatal. The 
vignettes presented brief accounts of 
situations leading to a decision to use gene 
editing. Each respondent read one of the 
four vignettes (adult therapy, prenatal 
therapy, adult enhancement or prenatal 
enhancement) assigned at random and was 
then asked, “Do you think he/they made 
a morally acceptable decision?” and “In 
his/their shoes would you make the same 
choice?” Responses were recorded on an 11-
point scale (from –5 for “No, definitely not” 
to +5 for “Yes, definitely”). Comparing the 
responses across vignettes reveals the effect 
of the experimental manipulations.
A multiple regression analysis (Table 1) 
shows that the therapy vignettes have, on 
average, higher scores than the enhancement 
vignettes on moral acceptability and on 
agreement that the respondent would make 
the same choice (to use gene editing) by over 
4 points in the 11-point scale. The prenatal 
compared with the adult recipient elicits a 
lower assessment of moral acceptability, and 
lower agreement that the respondent would 
make the same choice. Adding age, gender 
and education level of the respondents to 
the regression showed only that female 
respondents were more cautious about gene 
editing in general.
Across the 11 countries in the study, 
support is consistently greater for treatment 
than enhancement (between 3.3 and 5.2 
scale points). Similarly, there is greater 
support across all countries for intervention 
on adults than prenatals, but the magnitude 
effect of the target recipient is smaller 
(between 1.0 and 2.1 scale points). This is in 
agreement with the NAS report that there are 
“indications of public discomfort with using 
genome editing for what is deemed to be 
enhancement.”
A notable feature of the responses to 
the vignettes is how the range of opinion 
varies across the targets and purposes of the 
intervention (Fig. 1). For both adult therapy 
and prenatal enhancement the responses 
show broad agreement. The former is 
accepted with a median response of 8, 
whereas the latter is rejected with a median 
response just above zero. In contrast, adult 
enhancement and prenatal therapy appear 
to be morally ambiguous, reflected in very 
 Table 1  Regression coefficients for the target and purpose of gene editing  
(n = 11,716)a
Response variable




(R2) Percentage of total vari-
ance in “Would you make the 
same choice” accounted for by 
the model
Is it morally accept-
able?
1.89** –3.68** 0.36
Would you make the 
same choice?
1.47** –4.34** 0.37
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Across countries, a stronger precautionary 
judgment is evident for gene editing for 
therapy and enhancement in the prenatal 
compared with the adult scenario. This is 
somewhat counterintuitive. For example, 
assuming successful use in the therapeutic 
context, gene editing at the prenatal stage 
will have greater positive impact on the 
future outcomes of the recipient, simply 
because the recipient will live fewer years 
with a medical disability, compared 
with intervention in adulthood. In the 
enhancement context, prenatal intervention 
will arguably cause less distress than in the 
adult context. In adults, concerns about the 
violation of the sense of self, or of personal 
authenticity, are often presented as reasons 
to avoid enhancement6,7. Concerns about 
authenticity violations in the prenatal 
context are likely to be less compelling to 
many people, although there may be other 
ethical considerations that again tip the 
balance. Such issues will need to be critically 
interrogated in the deliberation over the 
uses of gene-editing technology. Although 
the US public joins people in the UK and 
Spain in being a little less negative than other 
EEA-10 countries about adult enhancement, 
differences between the United States and 
the EEA-10 countries are notable by their 
absence.
As with many other technologies, the 
public’s attention is on the applications 
or uses; these drive moral judgments. Yet 
scientific experts tend to focus on the 
technology itself. This harks back to the 
old struggle between regulating the process 
(the technology) or the applications (uses 
of the technology) that has caused so many 
problems for agricultural biotech in Europe8. 
Focusing on the technology will lead to 
inconsistent regulation, always lagging 
behind scientific progress. Focusing on uses 
will also present challenges: if countries 
opt for different regulations on the uses 
and target recipients of gene editing, some 
people may take to medical tourism. Should 
policy prioritize national interests or be 
transnational to reduce the risks associated 
with diverging policies? Perhaps it is time 
to set up a multinational institutional 
structure to guide innovative technological 
applications that are societally contentious.
A final word on the value of surveys in 
this controversial territory. Public opinion 
cannot and should not tell us what is right 
to do. However, as the NAS report notes, 
“Public participation should be incorporated 
into the policy-making process for human 
genome editing and should include ongoing 
monitoring of public attitudes, informational 
respondents view gene editing through a 
critical lens because of associations with 
genetically modified organisms (GMOs)? 
The answer is no; fewer than 3% mentioned 
GMOs. Other issues that did not feature 
beyond 1% or 2% included ‘designer babies’ 
and some of the ethical questions around 
human enhancement—increasing social 
disparities, obtaining an unfair advantage 
and undermining character.
Turning to differences between countries, 
we calculated the median scores for the 
four experimental vignettes (Fig. 2). We 
show the median rather than the mean, 
because in some countries at least half 
of the respondents gave a zero for the 
enhancement vignettes. The differing 
assessments of ‘therapy’ (between 5 and 9) 
versus ‘enhancement’ (between 0 and 4) 
highlight the fact that it is the application, 
rather than the technology itself, that is the 
critical issue for the public. Gene editing as 
applied to ‘adult therapy ’ receives consistent 
support across all countries. And although 
there are differences between countries over 
the use of gene editing for prenatal therapy, 
it is supported in the majority of countries. 
More than half of the sample in Austria, 
Denmark, Germany, Hungary, Iceland, Italy, 
the Netherlands, Portugal and the UK say 
they would not use gene editing for prenatal 
enhancement. This pattern is also seen in 
Austria, Denmark and Germany for adult 
enhancement.
Figure 1  Would you make the same decision? Box plots of survey responses to each gene editing 
vignette (adult therapy, prenatal therapy, adult enhancement or prenatal enhancement). The boxes 
show the 25th to 75th percentile responses and the median, the horizontal line (n = 11,716).
Figure 2  National differences on “Would you make the same decision?” (n = 11,716). ES, Spain; PT, 
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deficits, and emerging concerns about issues 
surrounding enhancement.” This survey is a 
contribution to understanding the practical 
and contextual dimensions of the ethical 
question; how can gene-editing technology 
contribute to human flourishing?
Note: Any Supplementary Information and Source Data 
files are available in the online version of the paper.  
Editor’s note: This article has been peer-reviewed.
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Gaps in current ethical standards
Although the US team abided by the most 
recent ethical standards for human genome 
editing, there remain critical gaps in these 
standards. According to guidelines issued last 
year by the US National Academy of Sciences 
(NAS; Washington, DC) and the International 
Society for Stem Cell Research (ISSCR), germ-
line editing of nuclear DNA is permissible only 
if scientific work is limited to in vitro embryo 
research; no edited human embryos ought to 
be implanted for reproduction at this time2,3. 
Unlike the ISSCR, however, the NAS goes fur-
ther to specify ten necessary conditions under 
which, in the future, in vitro germline editing 
research might be permitted to cross over into 
first-in-human clinical trials for reproduction 
(see Table 1).
Among these requirements, we highlight 
the following three: (1) that there must be 
no reasonable alternatives to reproductive 
embryo editing; (2) that embryo editing 
be done only to prevent a serious disease 
or condition; and (9 in Table 1) that there 
be “continued reassessment of both health 
and societal benefits and risks, with broad 
ongoing participation and input by the 
public.”
We believe these additional NAS 
conditions are significant not only because 
they allow for the very possibility of 
reproductive embryo editing in the future, 
but also because they offer guidance now 
for scientists pursuing in vitro embryo 
editing research aimed at possible future 
reproductive use. Conditions (1) and (2), 
for instance, should motivate researchers 
to deliberate carefully about which genetic 
diseases to target in their in vitro embryo 
editing studies. Researchers investigating the 
technical feasibility of reproductive embryo 
editing must first select a specific disease 
and then stick with it for the long haul. They 
cannot jump from one disease to another 
and still hope to have all the preclinical 
safety, efficacy, and proof-of-concept data 
necessary for the regulatory approval of any 
particular intervention. For example, if the 
US Food and Drug Administration (FDA; 
Rockville, MD) ever allows germline editing 
trials, it is likely to do so for a very specific 
guide RNA sequence on a CRISPR–Cas9 
construct intended to correct a particular 
gene mutation. The FDA will not give 
researchers carte blanche to pursue just any 
generic approach to CRISPR–Cas9 germline 
editing in a clinical trials context. Therefore, 
disease selection and specialization at the 
very start of in vitro research is crucial for 
teams aspiring to develop any future embryo 
editing intervention.
Query the merits of embryo editing 
for reproductive research now
To the Editor: Recently, a team from the 
United States used CRISPR–Cas9 on viable 
human embryos to correct a gene mutation 
that causes hypertrophic cardiomyopathy, 
a heritable heart condition in which the 
ventricle walls thicken to hinder proper 
blood flow1. For many, this announcement 
brings closer to reality the prospect of editing 
disease-associated mutations in fertility 
clinic embryos intended for reproductive 
use. The study certainly raises many 
scientific uncertainties and questions. But 
we contend that it also brings to light some 
questionable value assumptions that have 
largely flown under the radar in the social 
discourse around embryo editing. Here, we 
call attention to some of these assumptions 
and suggest that additional human embryo 
editing research may not be adequately 
justified until these issues have at least been 
openly acknowledged and debated. To be 
clear, our discussion is meant to apply only 
to ‘preclinical’ embryo editing research: 
that is, to corrective nuclear genome editing 
research performed in vitro with an eye 
toward eventual reproductive use under 
favorable regulatory circumstances. Our 
points do not necessarily apply to human 
embryonic genome editing studies for 
fundamental research aimed at silencing 
genes to understand their function in early 
development.
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